Oral Semaglutide Improves Blood Sugar, Weight, and Heart Risk Factors Within 3 Months
Real-world data from Italian diabetes centers shows oral semaglutide significantly improved blood sugar control, body weight, and cardiovascular risk markers after just three months.
Quick Facts
What This Study Found
Oral semaglutide produced significant short-term reductions in HbA1c and body weight, along with improvements in cardiovascular risk markers, in a real-world type 2 diabetes population.
Key Numbers
- 167 patients; mean age 66.5 years; baseline HbA1c 8.4%
- 83.2% on 7 mg dose
- HbA1c: 8.4% to 7.1% (-1.3%) in 3 months
- 30.5% lost more than 5% body weight (largest HbA1c drop: -1.9%)
- Significant cardiovascular risk reduction (p=0.04)
- Significant lipid parameter improvements
How They Did This
Multi-center real-world observational study across 4 Italian diabetes centers. Patients newly prescribed oral semaglutide were assessed at baseline and 3 months for glycemic control, weight, and cardiovascular risk parameters.
Why This Research Matters
Most semaglutide data comes from controlled clinical trials with strict inclusion criteria. This real-world study confirms that the benefits translate to everyday clinical practice, and that even the oral formulation — not just injections — delivers meaningful results quickly.
The Bigger Picture
With global shortages of injectable GLP-1 drugs and growing demand, oral semaglutide represents a critical alternative. Real-world evidence of rapid effectiveness supports its broader adoption and may help address access challenges.
What This Study Doesn't Tell Us
Observational design without a control group; 3-month timeframe limits long-term conclusions; Italian patient population may not generalize globally; specific effect sizes not provided in abstract.
Questions This Raises
- ?Do these short-term improvements persist at 6 and 12 months in real-world settings?
- ?How does oral semaglutide compare to injectable semaglutide in head-to-head real-world studies?
- ?Are there patient subgroups that benefit more from oral versus injectable formulations?
Trust & Context
- Key Stat:
- 3 months Significant improvements in HbA1c, weight, and cardiovascular risk markers seen with oral semaglutide
- Evidence Grade:
- Real-world observational study providing moderate evidence. Supports clinical trial findings but lacks the rigor of randomized controlled trials.
- Study Age:
- Published in 2025 with current-era data on oral semaglutide prescribing.
- Original Title:
- Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 18(6) (2025)
- Authors:
- Palazzi, Sara, Sentinelli, Federica, Zugaro, Antonella, Morgante, Sara, Santarelli, Livia, Melanzi, Sandra, De Mutiis, Annamaria, Piersanti, Deamaria, Macerola, Barbara, Iezzi, Marco, Mercuri, Pietro, Ferranti, Alessandro, Tienforti, Daniele, Cavallo, Maria Gisella, Barbonetti, Arcangelo, Baroni, Marco Giorgio
- Database ID:
- RPEP-12923
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Is oral semaglutide as effective as the injectable version?
Clinical trials suggest injectable semaglutide may have a slight edge in potency, but this real-world study shows the oral version still delivers meaningful improvements in blood sugar, weight, and heart risk factors within just 3 months.
Why is real-world data important for medications?
Clinical trials use strict criteria and controlled conditions. Real-world studies show how drugs work in everyday practice with diverse patients, comorbidities, and medication adherence patterns — giving a more practical picture of effectiveness.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12923APA
Palazzi, Sara; Sentinelli, Federica; Zugaro, Antonella; Morgante, Sara; Santarelli, Livia; Melanzi, Sandra; De Mutiis, Annamaria; Piersanti, Deamaria; Macerola, Barbara; Iezzi, Marco; Mercuri, Pietro; Ferranti, Alessandro; Tienforti, Daniele; Cavallo, Maria Gisella; Barbonetti, Arcangelo; Baroni, Marco Giorgio. (2025). Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.. Pharmaceuticals (Basel, Switzerland), 18(6). https://doi.org/10.3390/ph18060856
MLA
Palazzi, Sara, et al. "Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.." Pharmaceuticals (Basel, 2025. https://doi.org/10.3390/ph18060856
RethinkPeptides
RethinkPeptides Research Database. "Real-World Analysis of Short-Term Effectiveness of Oral Sema..." RPEP-12923. Retrieved from https://rethinkpeptides.com/research/palazzi-2025-realworld-analysis-of-shortterm
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.